A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Blom, Dirk; Hala, Tomas; A. Bolognese, Michael; Lillestol, Michael; D. Toth, Phillip; Burgess, Lesley; Češka, R; M. Roth, Eli; J. Koren, Michael; M. Ballantyne, Christie; Laura Monsalvo, Maria; Tsirtsonis, Kate; Bum Kim, Jae; C. Scott, Robert; M. Wasserman, Scott; A. Stein, Evan

doi:10.1056/nejmoa1316222

Public

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Published in New England Journal of Medicine • Mar 29, 2014

Authors:

Dirk Blom

Tomas Hala

Michael A. Bolognese

Abstract

BACKGROUND: Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies. We conducted a phase 3 trial to evaluate the safety and efficacy of 52 weeks of treatment with...

Subject

Evolocumab

Medicine

PCSK9

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!